These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

130 related items for PubMed ID: 27756037

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Time-dependent Changes of Atherosclerotic LDL Complexes after Smoking Cessation.
    Komiyama M, Shimada S, Wada H, Yamakage H, Satoh-Asahara N, Shimatsu A, Akao M, Morimoto T, Takahashi Y, Hasegawa K.
    J Atheroscler Thromb; 2016 Nov 01; 23(11):1270-1275. PubMed ID: 27298048
    [Abstract] [Full Text] [Related]

  • 4. α1-Antitrypsin low-density-lipoprotein serves as a marker of smoking-specific oxidative stress.
    Wada H, Ura S, Satoh-Asahara N, Kitaoka S, Mashiba S, Akao M, Abe M, Ono K, Morimoto T, Fujita M, Shimatsu A, Takahashi Y, Hasegawa K.
    J Atheroscler Thromb; 2012 Nov 01; 19(1):47-58. PubMed ID: 22027559
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Pitavastatin: novel effects on lipid parameters.
    Chapman MJ.
    Atheroscler Suppl; 2011 Nov 01; 12(3):277-84. PubMed ID: 22152282
    [Abstract] [Full Text] [Related]

  • 7. Comparative effects of high-dose atorvastatin versus moderate-dose rosuvastatin on lipid parameters, oxidized-LDL and inflammatory markers in ST elevation myocardial infarction.
    Aydin MU, Aygul N, Altunkeser BB, Unlu A, Taner A.
    Atherosclerosis; 2015 Apr 01; 239(2):439-43. PubMed ID: 25697576
    [Abstract] [Full Text] [Related]

  • 8. The effect of rosuvastatin on low-density lipoprotein subfractions in patients with impaired fasting glucose.
    Rizos CV, Kostapanos MS, Rizos EC, Tselepis AD, Elisaf MS.
    J Cardiovasc Pharmacol Ther; 2015 May 01; 20(3):276-83. PubMed ID: 25237153
    [Abstract] [Full Text] [Related]

  • 9. Statin treatment alters serum n-3 to n-6 polyunsaturated fatty acids ratio in patients with dyslipidemia.
    Nozue T, Michishita I.
    Lipids Health Dis; 2015 Jul 07; 14():67. PubMed ID: 26149129
    [Abstract] [Full Text] [Related]

  • 10. Highly absorptive curcumin reduces serum atherosclerotic low-density lipoprotein levels in patients with mild COPD.
    Funamoto M, Sunagawa Y, Katanasaka Y, Miyazaki Y, Imaizumi A, Kakeya H, Yamakage H, Satoh-Asahara N, Komiyama M, Wada H, Hasegawa K, Morimoto T.
    Int J Chron Obstruct Pulmon Dis; 2016 Jul 07; 11():2029-34. PubMed ID: 27616885
    [Abstract] [Full Text] [Related]

  • 11. A novel oxidized low-density lipoprotein marker, serum amyloid A-LDL, is associated with obesity and the metabolic syndrome.
    Kotani K, Satoh N, Kato Y, Araki R, Koyama K, Okajima T, Tanabe M, Oishi M, Yamakage H, Yamada K, Hattori M, Shimatsu A, Japan Obesity and Metabolic Syndrome Study Group.
    Atherosclerosis; 2009 Jun 07; 204(2):526-31. PubMed ID: 19007930
    [Abstract] [Full Text] [Related]

  • 12. Effects of rosuvastatin on serum lipids and arteriosclerosis in dyslipidemic patients with cerebral infarction.
    Deguchi I, Horiuchi Y, Hayashi T, Sehara Y, Kato Y, Ohe Y, Fukuoka T, Maruyama H, Sano H, Nagamine Y, Tanahashi N.
    J Stroke Cerebrovasc Dis; 2014 Sep 07; 23(8):2007-2011. PubMed ID: 25066602
    [Abstract] [Full Text] [Related]

  • 13. Effect of Extended-Release Niacin on High-Density Lipoprotein (HDL) Functionality, Lipoprotein Metabolism, and Mediators of Vascular Inflammation in Statin-Treated Patients.
    Yadav R, Liu Y, Kwok S, Hama S, France M, Eatough R, Pemberton P, Schofield J, Siahmansur TJ, Malik R, Ammori BA, Issa B, Younis N, Donn R, Stevens A, Durrington P, Soran H.
    J Am Heart Assoc; 2015 Sep 15; 4(9):e001508. PubMed ID: 26374297
    [Abstract] [Full Text] [Related]

  • 14. Effect of atorvastatin versus rosuvastatin on inflammatory biomarkers and LV function in type 2 diabetic patients with dyslipidemia.
    Werida R, Khairat I, Khedr NF.
    Biomed Pharmacother; 2021 Mar 15; 135():111179. PubMed ID: 33401219
    [Abstract] [Full Text] [Related]

  • 15. A Multi-Center, Open-Label, Two-Arm Parallel Group Non-inferiority Randomized Controlled Trial Evaluating the Effect of Pitavastatin, Compared to Atorvastatin, on Glucose Metabolism in Prediabetics with Hypertension and Dyslipidemia: Rationale and Design for the China Hemoglobin A1c Metabolism Protection Union Study (CAMPUS).
    Zhang J, Shao Y, Liu Y, Tao J.
    Cardiovasc Drugs Ther; 2018 Dec 15; 32(6):581-589. PubMed ID: 30187345
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Influence of atorvastatin on serum amyloid A-low density lipoprotein complex in hypercholesterolemic patients.
    Kotani K, Yamada T, Miyamoto M, Ishibashi S, Taniguchi N, Gugliucci A.
    Pharmacol Rep; 2012 Dec 15; 64(1):212-6. PubMed ID: 22580538
    [Abstract] [Full Text] [Related]

  • 18. Pitavastatin: an overview.
    Saito Y.
    Atheroscler Suppl; 2011 Nov 15; 12(3):271-6. PubMed ID: 22152281
    [Abstract] [Full Text] [Related]

  • 19. Clinically Administered Doses of Pitavastatin and Rosuvastatin.
    Katanasaka Y, Hirano S, Sunagawa Y, Miyazaki Y, Sato H, Funamoto M, Shimizu K, Shimizu S, Sari N, Hasegawa K, Morimoto T.
    Int Heart J; 2021 Nov 15; 62(6):1379-1386. PubMed ID: 34853228
    [Abstract] [Full Text] [Related]

  • 20. Comparative long-term efficacy and tolerability of pitavastatin 4 mg and atorvastatin 20-40 mg in patients with type 2 diabetes mellitus and combined (mixed) dyslipidaemia.
    Gumprecht J, Gosho M, Budinski D, Hounslow N.
    Diabetes Obes Metab; 2011 Nov 15; 13(11):1047-55. PubMed ID: 21812889
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.